Stocksigma LogoStocksigma Logo

Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion

Laurus Labs delivered strong 1H FY27 results, with revenue rising 31% YoY to ₹4,233 Cr, EBITDA jumping 72% YoY to ₹1,406 Cr (margins expanded 780 bps to

Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion

Laurus Labs Ltd · Investor Presentation · 29 Oct 2026, 8:48 pm

Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion Laurus Labs delivered strong 1H FY27 results, with revenue rising 31% YoY to ₹4,233 Cr, EBITDA jumping 72% YoY to ₹1,406 Cr (margins expanded 780 bps to 33.2%), and net profit increasing 126% YoY to ₹809 Cr. Growth was powered by CDMO small molecules (+77% YoY to ₹1,710 Cr). For Q2 FY27, revenue reached ₹2,206 Cr (+33% YoY) and PAT hit ₹441 Cr (+126% YoY). The company announced strategic acquisitions—a 60% stake in Galenvs and 52% in SI &C Resins—to enhance oligonucleotide and peptide capabilities, backed by a planned >₹3,000 Cr capex over FY27–FY28.

Original exchange filing (PDF)

More announcements from Laurus Labs Ltd

All Laurus Labs Ltd announcements